249 results found

Firms of auditors around the country will be breathing a huge sigh of relief next month. From 6 April, under new rules introduced by the Companies Act 2006, auditors will be able to limit their liability for negligence, default, breach of duty or breach of trust, in relation to audit work carried out for their corporate clients.

Force majeure clauses have come into sharp focus recently. These clauses are intended to govern what happens if an event beyond the control of the parties affects the performance of a contract.

It is not unusual for a commercial contractual relationship to encounter difficulties and, in some cases, an ongoing relationship would simply be unworkable.

The House of Lords has recently provided guidance on the law of novelty, in particular, what constitutes a disclosure and what is meant by enablement. The case in question was between Synthon BV and SmithKline Beecham plc and the dispute related to who was first to disclose, in a fully enabling fashion, paroxetine methanesulfonate.

The common understanding of "the public" probably conjures up images of a large gathering of people who are audience to an act such as the showing of a film or performance of a play.

The European Commission's long-awaited draft revised Vertical Block Exemption Regulation (VBER) and Vertical Guidelines were published earlier this month

The Competition and Markets Authority (‘CMA') has issued guidance to Government setting out its recommendations on the implementation of the new competition regime for digital markets.

We've posted about this dispute several times before (on the initial filing, the UK version, and the EC antitrust complaint). Now, with the California judgment finally out, what's the verdict?

Most favoured nation clauses (MFNs) are once again in the competition law spotlight.

The global biopharma market continues to expand and is predicted to continue doing so for many years to come. A review of recent financial and biopharma press coverage indicates that mergers and acquisitions remain prevalent within this industry. Recent press coverage also indicates that there are now thousands of small biotech companies worldwide and that larger companies are looking to expand their product portfolios by cherry picking the best of these smaller companies.

Custom audience products involve you providing personal data of your customers to a third party, usually a social media platform, which, via a matching process, determines which of your customers are also users of the SMP.

More than six years after its publication, Regulation (EU) No 536/2014 on clinical trials (the "EU Clinical Trials Regulation")

On 10 September 2021 the European Commission released a policy brief on the role of competition law in realising the European Green Deal

Digital platforms continue to be a hot topic for competition policy. Both the Commission and the CMA have been active over the last year in proposing and consulting on ways to ensure the effective competition in digital markets.

To that end, the Commission recently published a Working Paper setting out the current guidelines on so-called "dual role" agents.

The House of Commons Digital, Culture, Media and Sport Committee has recently published a significant report on its inquiry into the Economics of Music Streaming.

In previous articles we have highlighted the low number of Notified Bodies as one of the medical device industry's most pressing concerns ahead of the date of application of the EU MDR, which is now only weeks away.

As reported in last week's post, on 20 January 2021 Birss J handed down what may be his last first instance decision before his elevation to the Court of Appeal.